BioAdaptives Valuation
| BDPT Stock | USD 0.10 0.01 9.09% |
BioAdaptives seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of BioAdaptives from analyzing the firm fundamentals such as Current Valuation of 544.74 K, shares owned by insiders of 7.39 %, and Return On Asset of -3.43 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioAdaptives' price fluctuation is out of control at this time. Calculation of the real value of BioAdaptives is based on 3 months time horizon. Increasing BioAdaptives' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
BioAdaptives' intrinsic value may or may not be the same as its current market price of 0.10, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.1 | Real 0.0845 | Hype 0.1 | Naive 0.11 |
The intrinsic value of BioAdaptives' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioAdaptives' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioAdaptives helps investors to forecast how BioAdaptives pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioAdaptives more accurately as focusing exclusively on BioAdaptives' fundamentals will not take into account other important factors: BioAdaptives Total Value Analysis
BioAdaptives is currently projected to have valuation of 544.74 K with market capitalization of 144.44 K, debt of 450.26 K, and cash on hands of 49.58 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioAdaptives fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
544.74 K | 144.44 K | 450.26 K | 49.58 K |
BioAdaptives Investor Information
The company recorded a loss per share of 0.02. BioAdaptives had not issued any dividends in recent years. Based on the key indicators related to BioAdaptives' liquidity, profitability, solvency, and operating efficiency, BioAdaptives is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.BioAdaptives Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioAdaptives has an asset utilization ratio of 13.31 percent. This implies that the Company is making $0.13 for each dollar of assets. An increasing asset utilization means that BioAdaptives is more efficient with each dollar of assets it utilizes for everyday operations.BioAdaptives Ownership Allocation
BioAdaptives holds a total of 160.49 Million outstanding shares. BioAdaptives shows 7.4 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BioAdaptives Profitability Analysis
The company reported the previous year's revenue of 19.78 K. Net Loss for the year was (1.05 M) with profit before overhead, payroll, taxes, and interest of 10.11 K.About BioAdaptives Valuation
The pink sheet valuation mechanism determines BioAdaptives' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of BioAdaptives based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioAdaptives. We calculate exposure to BioAdaptives's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioAdaptives's related companies.BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada. Bioadaptives operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 3 people.
8 Steps to conduct BioAdaptives' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioAdaptives' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioAdaptives' valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioAdaptives' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioAdaptives' revenue streams: Identify BioAdaptives' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioAdaptives' industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioAdaptives' growth potential: Evaluate BioAdaptives' management, business model, and growth potential.
- Determine BioAdaptives' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioAdaptives' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
BioAdaptives Growth Indicators
Investing in growth stocks can be very risky. If the company such as BioAdaptives does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 20.4 M | |
| Retained Earnings | -6.7 M |
Additional Tools for BioAdaptives Pink Sheet Analysis
When running BioAdaptives' price analysis, check to measure BioAdaptives' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAdaptives is operating at the current time. Most of BioAdaptives' value examination focuses on studying past and present price action to predict the probability of BioAdaptives' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAdaptives' price. Additionally, you may evaluate how the addition of BioAdaptives to your portfolios can decrease your overall portfolio volatility.